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Brief CommunicationsStenting versus coronary artery bypass grafting for unprotected left
main coronary artery disease: Ameta-analysis of comparative studies
Hisato Takagi, MD, PhD, Norikazu Kawai, MD, and Takuya Umemoto, MD, PhD, Shizuoka, JapanAlthough coronary artery bypass grafting (CABG) is cur-
rently recommended to treat unprotected left main coronary
artery (LMCA) disease, the treatment of this disorder by per-
cutaneous coronary intervention represents a considerable
challenge for interventional cardiologists.1 Several studies
have analyzed the treatment of unprotected LMCA disease
with CABG versus percutaneous coronary intervention
with stents (PCI-S), but no meta-analyses of these studies
have been conducted to date. To compare the treatment of
unprotected LMCA disease with PCI-S versus CABG, we
performed a meta-analysis of comparative studies for pre-
vention of death, repeated revascularization, and major ad-
verse cardiac and cerebrovascular events (MACCEs) at
follow-up.
MATERIALS AND METHODS
All comparative studies of PCI-S (with bare metal or drug-eluting stents)
versus CABG (conventional or off-pump CABG) enrolling patients with
unprotected LMCA disease were identified by means of a 2-level search
strategy. First, a public domain database (MEDLINE) was searched with
a web-based search engine (PubMed). Second, relevant studies were iden-
tified through a manual search of secondary sources, including references
of initially identified articles and a search of reviews and commentaries.
The MEDLINE database was searched from January 1966 to March
2008. MeSH keywords included coronary artery bypass; angioplasty,
transluminal, percutaneous coronary; and stents. Studies considered for
inclusion met the following criteria: the study design was comparative
(randomized controlled or nonrandomized observational); the study
population consisted of patients with unprotected LMCA disease; patients
were assigned to undergo PCI-S versus CABG; and main outcomes in-
cluded death, repeated revascularization, or MACCEs (death, myocardial
infarction, stroke, or repeated revascularization) at follow-up. Data regard-
ing detailed inclusion criteria, stent type, duration of follow-up, and nega-
tive outcomes (death, repeated revascularization, and MACCEs) at
follow-up were abstracted as available from each individual study. Adjusted
risk estimates for nonrandomized controlled comparisons and crude risk ra-
tios for randomized controlled comparisons were pooled after logarithmic
transformation according to a random-effects model with generic inverse
variance weighting. Interstudy heterogeneity was analyzed by means of
standard c2 tests.
From the Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka,
Japan.
Received for publication March 7, 2008; accepted for publication June 15, 2008.
Address for reprints: Hisato Takagi,MD, PhD, Department of Cardiovascular Surgery,
Shizuoka Medical Center, 762-1 Nagasawa, Shimizu-cho, Sunto-gun, Shizuoka
411-8611, Japan (E-mail: kfgth973@ybb.ne.jp).
J Thorac Cardiovasc Surg 2009;137:e54-7
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2008.06.006e54 The Journal of Thoracic and Cardiovascular SurRESULTS
Our search identified 6 comparative studies1-6 of PCI-S
versus CABG that had enrolled patients with unprotected
LMCA disease. These included 1 randomized controlled
trial2 and 5 nonrandomized observational studies.1,3-6 We
excluded 2 nonrandomized observational studies, by Brener
and colleagues (2008) and Sanmartı´n and associates (2007),
because adjusted risk estimates could not be abstracted. In
total, our meta-analysis included data on 2181 patients
with unprotected LMCA disease assigned to undergo
PCI-S (n¼ 1006) or CABG (n¼ 1175). The baseline patient
and procedural characteristics are summarized in Table 1.
For death at follow-up, 3 studies1,2,4 demonstrated a statisti-
cally nonsignificant benefit of PCI-S relative to CABG,
whereas 2 studies3,6 demonstrated a statistically nonsignifi-
cant benefit of CABG relative to PCI-S. Pooled analysis of
the 5 studies reporting this outcome demonstrated no
significant difference in death rate between PCI-S and
CABG (P¼ .97; Figure 1, A). There was no significant inter-
study heterogeneity of results (P ¼ .36). For repeated revas-
cularization at follow-up, all 4 studies reporting this
outcome1-3,6 demonstrated a statistically significant benefit
of CABG relative to PCI-S. Pooled analysis of these 4 studies
demonstrated a statistically significant increase in repeated
revascularization with PCI-S relative to CABG (P <
.00001; Figure 1, B). There was no significant interstudy
heterogeneity of results (P ¼ .25). For MACCEs at follow-
up, 2 studies1,5 demonstrated a statistically nonsignificant
benefit of PCI-S relative to CABG, whereas 1 study2 demon-
strated a statistically nonsignificant benefit of CABG relative
to PCI-S. Pooled analysis of the 3 studies that reportedMAC-
CEs as an outcome demonstrated a statistically nonsignifi-
cant reduction in MACCEs with PCI-S relative to CABG
(P ¼ .32; Figure 1, C). There was no significant interstudy
heterogeneity of results (P ¼ .07). When data were pooled
with a fixed-effects model, the overall results of our analysis
were not substantively altered.
DISCUSSION
On the basis of this meta-analysis, CABG is likely to pro-
vide better results than PCI-S not in terms of death and
MACCEs but in terms of repeated revascularization at 6
months to 3 years of follow-up. Main limitations of our anal-
ysis are the following: only a single randomized, controlled
trial was included, and it was small; both bare metal and
drug-eluting stents were used in the PCI-S group; both con-
ventional and off-pump CABG were performed in thegery c January 2009
Brief CommunicationsTABLE 1. Baseline patient and procedural characteristics
Seung
et al, 20083
Buszman
et al, 20082
Palmerini
et al, 20074
Chieffo
et al, 20061
Lee
et al, 20065
Palmerini
et al, 20066
Design Observational Randomized Observational Observational Observational Observational
Follow-up 1017 d* (IQR 688–
1451 d), 1152 d*
(IQR 681–1590 d)
1 y 2 y 1 y 5.6  3.9 mo,
6.7  6.2 mo
417 d* (2–830 d),
430 d* (105–
730 d)
P valuey .26 .439
Patients (No.) 542,z 542z 52, 53 98, 161 107, 142 50, 123 157, 154
Age (y) 64* (IQR 56–71),
64* (IQR 56–70)
60.6  10.5,
61.3  8.4
81* (75–88),
78* (75–88)
63.6  10.3,
67.5  9.7
72  15,
70  10
73.0  10.9,
69.3  9.5
P valuey .41 .69 <.001 .002 .33 .002
Male (%) 71.6%, 71.2% 60%, 73% 54%, 66% NR 50%, 76% 70.1%, 76.0%
P valuey .95 .13 .06 <.01 .296
Ejection
fraction (%)
61%* (IQR 54%–
66%), 61%*
(IQR 55%–66%)
53.5%  10.7%,
53.7%  6.7%
50%* (20%–70%),
53%* (25%–
78%)
52.0%  10.4%,
52.2%  11.4%
51%  15%,
52  10%
51.8  13.8%,
54.6  12%
P valuey .62 .86 .68 .91 .64 .069
Clinical
presentation
Stable angina
(%)
29.2%, 28.4%x CCS class 3.1  1.0,
2.8  1.0
NR NR 34%, 55% 26.8%, 27.9%
P valuey .17 NR .917
Unstable
angina (%)
57.4%, 57.9%x Acute coronary
syndrome 77%,
52%
31.8%, 21.8% 46%, 25% Braunwald class IBþ
IIB 13.4%, 20.1%
(P ¼ .149); IIIB
13.4%, 7.8% (P
¼ .157)
P valuey <.001 .08 NR
Myocardial
infarction (%)
10.7%,k 11.1%kx NR 20%, 20% 39.5%,{ 31.2%{
P valuey NR .157
Surgical risk
EuroSCORE NR 3.3  2.3,
3.5  2.3
8* (4–18),
7* (3–14)
4.4  3.6,
4.3  3.4
NR 6* (0–18),
5* (0–14)
P valuey .65 <.001 .85 .032
Parsonnet score NR 22.5* (12.5–38.5),
14* (5–36)
NR 18.3  10.9,
13.7  9.7
16.5* (2.5–37), 12.5*
(2–36)
P valuey <.001 <.01 .004
Coexisting
conditions
Diabetes
mellitus (%)
32.7%, 33.0% 19%, 17% 31%, 26% 18.7%, 23.2% 36%, 31% 26.1%, 25.3%
P valuey .95 .80 .72 .44 .48 .976
Hypertension
(%)
49.4%, 50.0% 75%, 70% 77%, 73% 58.8%, 76.0% 88%, 81% 69.4%, 72.7%
P valuey .9 .78 .67 .006 .37 .605
Hyperlipidemia
(%)
29.3%, 30.1% 65%, 60% 53%, 47% 70.0%, 69.0% 74%, 72% 62.4%, 72.1%
P valuey .84 .78 .43 .89 .85 .09
Procedural
characteristics
DES (%) 71.1% 35% 100% 100% 100% 59.9%
Distal LMCA
disease (%)
51.7%, 52.2% 56%, 60% 89%, 70% 81.3%, NR 60%, NR 80.3%, 82.5%
P valuey .9 .63 <.001 NR NR .742
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studies were relatively short. In an attempt to correct for and
minimize selection bias in nonrandomized observational
studies, we pooled adjusted risk estimates. Nevertheless,
these findings should be viewed in light of the need to
wait for the results of ongoing large randomized, controlled
trials (eg, COMBAT, SYNTAX, and REVASCULARIZE
studies) before drawing any definitive conclusion.
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TABLE 1. Continued
Seung
et al, 20083
Buszman
et al, 20082
Palmerini
et al, 20074
Chieffo
et al, 20061
Lee
et al, 20065
Palmerini
et al, 20066
Off-pump
CABG (%)
42% 2% 21% 39.5% 0% 0%
Arterial
conduit (%)
98.4% 72%# 93%** NR 96%yy 94.2%**
Pharmacologic
treatment
Percutaneous
coronary
intervention
with stents
Aspirin indefinitelyþ
clopidogrel or
ticlopidine 1 mo
(BMS) or
clopidogrel6 mo
(DES)
Double
antiplatelet
treatment
1 y
Aspirin indefinitely
þ ticlopidine or
clopidogrel
3–12 mo
NR Aspirin indefinitelyþ
clopidogrel6mo
NR
CABG NR NR
When two values are given, the first represents percutaneous coronary intervention with stenting and the second represents coronary artery bypass grafting. IQR, Interquartile range;
NR, not reported; CCS, Canadian Cardiovascular Society; DES, drug-eluting stents; LMCA, left main coronary artery; CABG, coronary artery bypass grafting; BMS, bare metal
stent. *Median. yReported in each individual study. zPropensity-matched patients from 1102 in the percutaneous coronary intervention with stenting group and 1138 in the coronary
artery bypass grafting group. xP ¼ .97. kNon–ST elevation. {Non-Q wave. #Left internal thoracic artery. **Internal thoracic artery. yyInternal thoracic artery to left anterior de-
scending coronary artery.e56 The Journal of Thoracic and Cardiovascular Surgery c January 2009
Brief CommunicationsFIGURE 1. Outcomes and meta-analyses at follow-up for death (A), repeated revascularization (B), and major adverse cardiac and cerebrovascular events
(MACCE; C). PCI-S, Percutaneous coronary intervention with stents; CABG, coronary artery bypass grafting; LMCA, left main coronary artery; CI, confi-
dence interval.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 1 e57
